Encephalopathy: Cause, Pathogenesis, and Treatment

Abstract

Encephalopathy refers to diffuse brain dysfunction caused by various systemic pathological processes such as systemic infections, metabolic disorders, and organ failure. This condition poses a formidable challenge in neurocritical care, with major subtypes encompassing sepsis-associated encephalopathy, hepatic encephalopathy, hypoxic–ischemic encephalopathy, diabetic encephalopathy, uremic encephalopathy, and toxic encephalopathy. The current therapeutic landscape reveals a critical deficiency in effective neuroprotective interventions, highlighting an urgent need for novel treatment strategies. Small-molecule compounds, particularly those derived from natural products, offer a promising therapeutic paradigm due to their multitarget capabilities and potential for network-level modulation of pathogenic processes. However, advancement in this field remains constrained by several fundamental limitations: fragmented mechanistic insights, ill-defined target networks, and insufficient clinical translation. To address these challenges, this review systematically synthesizes contemporary evidence to delineate the etiopathogenesis of these encephalopathies, with particular emphasis on the molecular mechanisms and cellular targets of small molecule drugs (especially natural products). Through a critical assessment of current research limitations, this review aims to establish a robust framework and provide forward-looking perspectives to guide the development of targeted neuroprotective strategies and their clinical translation.

Keywords

cause / clinical translation / encephalopathy / pathological mechanism / therapeutic potential

References

[1] T. Tao, M. Liu, M. Chen, et al., “Natural Medicine in Neuroprotection for Ischemic Stroke: Challenges and Prospective,” Pharmacology & Therapeutics 216 (2020): 107695.

[2] C. Ge, W. Chen, L. Zhang, Y. Ai, Y. Zou, and Q. Peng, “Chemogenetic Activation of the HPC-mPFC Pathway Improves Cognitive Dysfunction in Lipopolysaccharide -induced Brain Injury,” Theranostics 13, no. 9 (2023): 2946–2961.

[3] H. Qu, J. Wu, Y. Pan, et al., “Biomimetic Nanomodulator Regulates Oxidative and Inflammatory Stresses to Treat Sepsis-Associated Encephalopathy,” ACS Nano 18, no. 41 (2024): 28228–28245.

[4] H. Kadry, B. Noorani, and L. Cucullo, “A Blood-brain Barrier Overview on Structure, Function, Impairment, and Biomarkers of Integrity,” Fluids Barriers CNS 17, no. 1 (2020): 69.

[5] M. D. Sweeney, A. P. Sagare, and B. V. Zlokovic, “Blood-brain Barrier Breakdown in Alzheimer Disease and Other Neurodegenerative Disorders,” Nature Reviews Neurology 14, no. 3 (2018): 133–150.

[6] R. A. Towner, D. Saunders, N. Smith, et al., “Assessing Long-term Neuroinflammatory Responses to Encephalopathy Using MRI Approaches in a Rat Endotoxemia Model,” Geroscience 40, no. 1 (2018): 49–60.

[7] K. Erikson, H. Tuominen, M. Vakkala, et al., “Brain Tight Junction Protein Expression in Sepsis in an Autopsy Series,” Critical Care 24, no. 1 (2020): 385.

[8] O. Handa, J. Stephen, and G. Cepinskas, “Role of Endothelial Nitric Oxide Synthase-derived Nitric Oxide in Activation and Dysfunction of Cerebrovascular Endothelial Cells during Early Onsets of Sepsis,” American Journal of Physiology. Heart and Circulatory Physiology 295, no. 4 (2008): H1712–H1719.

[9] T. van der Poll, F. L. van de Veerdonk, B. P. Scicluna, and M. G. Netea, “The Immunopathology of Sepsis and Potential Therapeutic Targets,” Nature Reviews Immunology 17, no. 7 (2017): 407–420.

[10] Y. Li, F. Zhou, J. You, and X. Gong, “Annexin A1 Mitigates Blood-Brain Barrier Disruption in a Sepsis-Associated Encephalopathy Model by Enhancing the Expression of Occludin and Zonula Occludens-1 (ZO-1),” CNS Neuroscience & Therapeutics 30, no. 12 (2024): e70173.

[11] D. S. Kikuchi, A. C. P. Campos, H. Qu, et al., “Poldip2 mediates Blood-brain Barrier Disruption in a Model of Sepsis-associated Encephalopathy,” J Neuroinflammation 16, no. 1 (2019): 241.

[12] X. Huang, P. Wei, C. Fang, et al., “Compromised Endothelial Wnt/β-catenin Signaling Mediates the Blood-brain Barrier Disruption and Leads to Neuroinflammation in Endotoxemia,” J Neuroinflammation 21, no. 1 (2024): 265.

[13] N. Liang, Y. Li, C. Yuan, et al., “Caspase-11 Signaling Promotes Damage to Hippocampal CA3 to Enhance Cognitive Dysfunction in Infection,” Molecular Medicine 30, no. 1 (2024): 127.

[14] C. Wei, W. Jiang, R. Wang, et al., “Brain Endothelial GSDMD Activation Mediates Inflammatory BBB Breakdown,” Nature 629, no. 8013 (2024): 893–900.

[15] F. Leng and P. Edison, “Neuroinflammation and Microglial Activation in Alzheimer Disease: Where Do We Go from Here?,” Nature Reviews Neurology 17, no. 3 (2021): 157–172.

[16] X. Han, T. Xu, Q. Fang, et al., “Quercetin Hinders Microglial Activation to Alleviate Neurotoxicity via the Interplay between NLRP3 Inflammasome and Mitophagy,” Redox Biology 44 (2021): 102010.

[17] J. Fu and H. Wu, “Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation,” Annual Review of Immunology 41 (2023): 301–316.

[18] M. S. J. Mangan, E. J. Olhava, W. R. Roush, H. M. Seidel, G. D. Glick, and E. Latz, “Targeting the NLRP3 Inflammasome in Inflammatory Diseases,” Nat Rev Drug Discovery 17, no. 9 (2018): 688.

[19] Q. Zhao, G. Liu, Q. Ding, et al., “The ROS/TXNIP/NLRP3 Pathway Mediates LPS-induced Microglial Inflammatory Response,” Cytokine 181 (2024): 156677.

[20] C. A. Moraes, E. D. Hottz, D. Dos Santos Ornellas, et al., “Microglial NLRP3 Inflammasome Induces Excitatory Synaptic Loss Through IL-1β-Enriched Microvesicle Release: Implications for Sepsis-Associated Encephalopathy,” Molecular Neurobiology 60, no. 2 (2023): 481–494.

[21] H. Ding, S. Zhang, Z. Li, J. Zeng, and H. Zeng, “Hypercapnia Promotes NLRP3 Inflammasome Activation in Microglia by Activating P2×7R after Lipopolysaccharide-induced Activation of the TLR4/NF-κB Signaling Pathway,” Cytokine 185 (2025): 156806.

[22] V. S. Alves, J. P. da Silva, F. C. Rodrigues, et al., “P2×7 receptor Contributes to Long-term Neuroinflammation and Cognitive Impairment in Sepsis-surviving Mice,” Frontiers in Pharmacology 14 (2023): 1179723.

[23] C. Park, Z. Lei, Y. Li, et al., “Extracellular Vesicles in Sepsis Plasma Mediate Neuronal Inflammation in the Brain through miRNAs and Innate Immune Signaling,” J Neuroinflammation 21, no. 1 (2024): 252.

[24] J. A. Siddiqui, R. Pothuraju, P. Khan, et al., “Pathophysiological Role of Growth Differentiation Factor 15 (GDF15) in Obesity, Cancer, and Cachexia,” Cytokine & Growth Factor Reviews 64 (2022): 71–83.

[25] L. Chen, S. Luo, T. Liu, et al., “Growth Differentiation Factor 15 Aggravates Sepsis-induced Cognitive and Memory Impairments by Promoting Microglial Inflammatory Responses and Phagocytosis,” J Neuroinflammation 22, no. 1 (2025): 44.

[26] R. B. Price and R. Duman, “Neuroplasticity in Cognitive and Psychological Mechanisms of Depression: An Integrative Model,” Molecular Psychiatry 25, no. 3 (2020): 530–543.

[27] T. Fuchsberger and O. Paulsen, “Modulation of Hippocampal Plasticity in Learning and Memory,” Current Opinion in Neurobiology 75 (2022): 102558.

[28] R. Szelenberger, J. Kostka, J. Saluk-Bijak, and E. Miller, “Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery,” Current Neuropharmacology 18, no. 1 (2020): 51–64.

[29] M. Luciana and P. F. Collins, “Neuroplasticity, the Prefrontal Cortex, and Psychopathology-Related Deviations in Cognitive Control,” Annu Rev Clin Psychol 18 (2022): 443–469.

[30] J. C. Magee and C. Grienberger, “Synaptic Plasticity Forms and Functions,” Annual Review of Neuroscience 43 (2020): 95–117.

[31] L. Colucci-D'Amato, L. Speranza, and F. Volpicelli, “Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer,” International Journal of Molecular Sciences 21, no. 20 (2020): 7777.

[32] J. Grafman, “Conceptualizing Functional Neuroplasticity,” Journal of Communication Disorders 33, no. 4 (2000): 345–356.

[33] P. P. Jiang, S. S. Peng, S. Pankratova, P. Luo, P. Zhou, and Y. Chen, “Proteins Involved in Synaptic Plasticity Are Downregulated in the Cerebrospinal Fluid of Infants With Clinical Sepsis Complicated by Neuroinflammation,” Front Cell Neurosci 16 (2022): 887212.

[34] K. Xu, H. Li, B. Zhang, et al., “Integrated Transcriptomics and Metabolomics Analysis of the Hippocampus Reveals Altered Neuroinflammation, Downregulated Metabolism and Synapse in Sepsis-associated Encephalopathy,” Frontiers in Pharmacology 13 (2022): 1004745.

[35] S. T. Anderson, S. Commins, P. N. Moynagh, and A. N. Coogan, “Lipopolysaccharide-induced Sepsis Induces Long-lasting Affective Changes in the Mouse,” Brain, Behavior, and Immunity 43 (2015): 98–109.

[36] X. Y. Yin, X. H. Tang, S. X. Wang, et al., “HMGB1 mediates Synaptic Loss and Cognitive Impairment in an Animal Model of Sepsis-associated Encephalopathy,” J Neuroinflammation 20, no. 1 (2023): 69.

[37] C. Zhang, F. Tian, J. Peng, et al., “Serotonergic Neurotransmission Mediated Cognitive Dysfunction in Two Mouse Models of Sepsis-associated Encephalopathy,” CNS Neuroscience & Therapeutics 30, no. 3 (2024): e14655.

[38] T. Tufail, H. B. U. Ain, M. S. Virk, et al., “GABA (γ-aminobutyric acid) Enrichment and Detection Methods in Cereals: Unlocking Sustainable Health Benefits,” Food Chemistry 464, no. Pt 3 (2025): 141750.

[39] S. Gao, R. Shen, J. Li, et al., “N-acetyltransferase 10 Mediates Cognitive Dysfunction through the Acetylation of GABABR1 mRNA in Sepsis-associated Encephalopathy,” PNAS 121, no. 36 (2024): e2410564121.

[40] L. Zhang, Y. Z. Gao, C. J. Zhao, J. Y. Xia, J. J. Yang, and M. H. Ji, “Reduced Inhibitory and Excitatory Input onto Parvalbumin Interneurons Mediated by Perineuronal Net Might Contribute to Cognitive Impairments in a Mouse Model of Sepsis-associated Encephalopathy,” Neuropharmacology 225 (2023): 109382.

[41] C. S. Wang, E. T. Kavalali, and L. M. Monteggia, “BDNF Signaling in Context: From Synaptic Regulation to Psychiatric Disorders,” Cell 185, no. 1 (2022): 62–76.

[42] C. L. Ge, W. Chen, L. N. Zhang, Y. H. Ai, Y. Zou, and Q. Y. Peng, “Hippocampus-prefrontal Cortex Inputs Modulate Spatial Learning and Memory in a Mouse Model of Sepsis Induced by Cecal Ligation Puncture,” CNS Neuroscience & Therapeutics 29, no. 1 (2023): 390–401.

[43] J. S. Loh, W. Q. Mak, L. K. S. Tan, et al., “Microbiota-gut-brain Axis and Its Therapeutic Applications in Neurodegenerative Diseases,” Signal Transduct Target Ther 9, no. 1 (2024): 37.

[44] X. Wang, X. Wen, S. Yuan, and J. Zhang, “Gut-brain Axis in the Pathogenesis of Sepsis-associated Encephalopathy,” Neurobiology of Disease 195 (2024): 106499.

[45] H. J. Kim, H. Kim, J. H. Lee, and C. Hwangbo, “Toll-Like Receptor 4 (TLR4): New Insight Immune and Aging,” Immun Ageing 20, no. 1 (2023): 67.

[46] A. Płóciennikowska, A. Hromada-Judycka, K. Borzęcka, and K. Kwiatkowska, “Co-operation of TLR4 and Raft Proteins in LPS-induced Pro-inflammatory Signaling,” Cellular and Molecular Life Sciences 72, no. 3 (2015): 557–581.

[47] M. Stephens and P. Y. von der Weid, “Lipopolysaccharides Modulate Intestinal Epithelial Permeability and Inflammation in a Species-specific Manner,” Gut Microbes 11, no. 3 (2020): 421–432.

[48] K. J. O'Riordan, G. M. Moloney, L. Keane, G. Clarke, and J. F. Cryan, “The Gut Microbiota-immune-brain Axis: Therapeutic Implications,” Cell Rep Med 6, no. 3 (2025): 101982.

[49] R. Abdel-Haq, J. C. M. Schlachetzki, C. K. Glass, and S. K. Mazmanian, “Microbiome-microglia Connections via the Gut-brain Axis,” Journal of Experimental Medicine 216, no. 1 (2019): 41–59.

[50] H. Wang, M. Zhang, J. Li, et al., “Gut Microbiota Is Causally Associated with Poststroke Cognitive Impairment through Lipopolysaccharide and Butyrate,” J Neuroinflammation 19, no. 1 (2022): 76.

[51] M. G. Gareau, “The Microbiota-Gut-Brain Axis in Sepsis-Associated Encephalopathy,” mSystems 7, no. 4 (2022): e0053322.

[52] T. Wang, B. Chen, M. Luo, et al., “Microbiota-indole 3-propionic Acid-brain Axis Mediates Abnormal Synaptic Pruning of Hippocampal Microglia and Susceptibility to ASD in IUGR Offspring,” Microbiome 11, no. 1 (2023): 245.

[53] H. Fang, Y. Wang, J. Deng, et al., “Sepsis-Induced Gut Dysbiosis Mediates the Susceptibility to Sepsis-Associated Encephalopathy in Mice,” mSystems 7, no. 3 (2022): e0139921.

[54] Z. B. Huang, G. P. Zhang, C. X. Lu, et al., “Gut Microbiota-derived 3-indoleacetic Acid Confers a Protection against Sepsis-associated Encephalopathy through Microglial Aryl Hydrocarbon Receptors,” Experimental Neurology 384 (2025): 115055.

[55] E. R. Mann, Y. K. Lam, and H. H. Uhlig, “Short-chain Fatty Acids: Linking Diet, the Microbiome and Immunity,” Nature Reviews Immunology 24, no. 8 (2024): 577–595.

[56] H. Liao, H. Li, H. Bao, et al., “Short Chain Fatty Acids Protect the Cognitive Function of Sepsis Associated Encephalopathy Mice via GPR43,” Front Neurol 13 (2022): 909436.

[57] Z. Li, F. Zhang, M. Sun, et al., “The Modulatory Effects of Gut Microbes and Metabolites on Blood-brain Barrier Integrity and Brain Function in Sepsis-associated Encephalopathy,” PeerJ 11 (2023): e15122.

[58] L. Zhao, Z. Zhang, P. Wang, et al., “NHH Promotes Sepsis-associated Encephalopathy with the Expression of AQP4 in Astrocytes through the Gut-brain Axis,” J Neuroinflammation 21, no. 1 (2024): 138.

[59] M. R. Freeman and D. H. Rowitch, “Evolving Concepts of Gliogenesis: A Look Way Back and Ahead to the next 25 Years,” Neuron 80, no. 3 (2013): 613–623.

[60] Y. Liu, X. Shen, Y. Zhang, et al., “Interactions of Glial Cells with Neuronal Synapses, from Astrocytes to Microglia and Oligodendrocyte Lineage Cells,” Glia 71, no. 6 (2023): 1383–1401.

[61] F. Endo, A. Kasai, J. S. Soto, et al., “Molecular Basis of Astrocyte Diversity and Morphology across the CNS in Health and Disease,” Science 378, no. 6619 (2022): eadc9020.

[62] D. Zhu, P. Wang, X. Chen, et al., “Astrocyte-Derived Interleukin 11 Modulates Astrocyte-Microglia Crosstalk via Nuclear Factor-κB Signaling Pathway in Sepsis-Associated Encephalopathy,” Research (Wash D C) 8 (2025): 0598.

[63] D. D. Zhu, Y. L. Huang, S. Y. Guo, et al., “AQP4 Aggravates Cognitive Impairment in Sepsis-Associated Encephalopathy through Inhibiting Nav1.6-Mediated Astrocyte Autophagy,” Adv Sci (Weinh) 10, no. 30 (2023): e2306241.

[64] B. Mei, X. Xu, J. Weng, et al., “Activating Astrocytic α2A Adrenoceptors in Hippocampus Reduces Glutamate Toxicity to Attenuate Sepsis-associated Encephalopathy in Mice,” Brain, Behavior, and Immunity 117 (2024): 376–398.

[65] M. Colonna and O. Butovsky, “Microglia Function in the Central Nervous System During Health and Neurodegeneration,” Annual Review of Immunology 35 (2017): 441–468.

[66] L. V. G. Castro, C. F. Gonçalves-de-Albuquerque, and A. R. Silva, “Polarization of Microglia and Its Therapeutic Potential in Sepsis,” International Journal of Molecular Sciences 23, no. 9 (2022): 4925.

[67] X. Lv, M. Jia, X. Feng, et al., “STING Driving Synaptic Phagocytosis of Hippocampal Microglia/Macrophages Contributes to Cognitive Impairment in Sepsis-Associated Encephalopathy in Mice,” CNS neuroscience & therapeutics 30, no. 12 (2024): e70166.

[68] H. Y. Chung, J. Wickel, N. Hahn, et al., “Microglia Mediate Neurocognitive Deficits by Eliminating C1q-tagged Synapses in Sepsis-associated Encephalopathy,” Science Advances 9, no. 21 (2023): eabq7806.

[69] V. Sorrentino, K. J. Menzies, and J. Auwerx, “Repairing Mitochondrial Dysfunction in Disease,” Annual Review of Pharmacology and Toxicology 58 (2018): 353–389.

[70] Y. Zong, H. Li, P. Liao, et al., “Mitochondrial Dysfunction: Mechanisms and Advances in Therapy,” Signal Transduct Target Ther 9, no. 1 (2024): 124.

[71] D. Hu, H. Sheeja Prabhakaran, Y. Y. Zhang, G. Luo, W. He, and Y. C. Liou, “Mitochondrial Dysfunction in Sepsis: Mechanisms and Therapeutic Perspectives,” Critical Care 28, no. 1 (2024): 292.

[72] J. Wu, M. Zhang, S. Hao, et al., “Mitochondria-Targeted Peptide Reverses Mitochondrial Dysfunction and Cognitive Deficits in Sepsis-Associated Encephalopathy,” Molecular Neurobiology 52, no. 1 (2015): 783–791.

[73] L. Zhao, Y. Song, Y. Zhang, et al., “HIF-1α/BNIP3L Induced Cognitive Deficits in a Mouse Model of Sepsis-associated Encephalopathy,” Frontiers in immunology 13 (2022): 1095427.

[74] J. Ling, S. Yu, F. Xiong, and S. Li, “HSPB8 up-regulation Alleviates Cognitive Dysfunction in a Mouse Model of Sepsis-associated Encephalopathy,” International Immunopharmacology 122 (2023): 110448.

[75] P. Wang, L. Liang, Q. Ge, S. Liu, Z. Yang, and L. Jiang, “Dichloroacetate Attenuates Brain Injury through Inhibiting Neuroinflammation and Mitochondrial Fission in a Rat Model of Sepsis-associated Encephalopathy,” International Immunopharmacology 140 (2024): 112840.

[76] Y. Liu, H. Yang, N. Luo, et al., “An Fgr Kinase Inhibitor Attenuates Sepsis-associated Encephalopathy by Ameliorating Mitochondrial Dysfunction, Oxidative Stress, and Neuroinflammation via the SIRT1/PGC-1α Signaling Pathway,” Journal of translational medicine 21, no. 1 (2023): 486.

[77] Y. Dong, H. Kang, R. Peng, et al., “A Clinical-stage Nrf2 Activator Suppresses Osteoclast Differentiation via the Iron-ornithine Axis,” Cell metabolism 36, no. 8 (2024): 1679–1695.

[78] H. Duan, X. Yang, S. Cai, et al., “Nrf2 mitigates Sepsis-associated Encephalopathy-induced Hippocampus Ferroptosis via Modulating Mitochondrial Dynamic Homeostasis,” International Immunopharmacology 143, no. Pt 1 (2024): 113331.

[79] K. Newton, A. Strasser, N. Kayagaki, and V. M. Dixit, “Cell Death,” Cell 187, no. 2 (2024): 235–256.

[80] J. Yuan and D. Ofengeim, “A Guide to Cell Death Pathways,” Nature Reviews Molecular Cell Biology 25, no. 5 (2024): 379–395.

[81] Z. Li, D. Li, R. Chen, S. Gao, Z. Xu, and N. Li, “Cell Death Regulation: A New Way for Natural Products to Treat Osteoporosis,” Pharmacological Research 187 (2023): 106635.

[82] J. Sun, J. S. Fleishman, X. Liu, H. Wang, and L. Huo, “Targeting Novel Regulated Cell Death: Ferroptosis, Pyroptosis, and Autophagy in Sepsis-associated Encephalopathy,” Biomedicine & Pharmacotherapy 174 (2024): 116453.

[83] Z. Rao, Y. Zhu, P. Yang, et al., “Pyroptosis in Inflammatory Diseases and Cancer,” Theranostics 12, no. 9 (2022): 4310–4329.

[84] X. Zheng, W. Chen, F. Gong, Y. Chen, and E. Chen, “The Role and Mechanism of Pyroptosis and Potential Therapeutic Targets in Sepsis: A Review,” Frontiers in immunology 12 (2021): 711939.

[85] Y. Wang, X. Liu, Q. Wang, and X. Yang, “Roles of the Pyroptosis Signaling Pathway in a Sepsis-associated Encephalopathy Cell Model,” Journal of International Medical Research 48, no. 8 (2020): 300060520949767.

[86] Z. Dai, W. C. Liu, X. Y. Chen, X. Wang, J. L. Li, and X. Zhang, “Gasdermin D-mediated Pyroptosis: Mechanisms, Diseases, and Inhibitors,” Frontiers in immunology 14 (2023): 1178662.

[87] Q. Fu, Y. B. Zhang, C. X. Shi, et al., “GSDMD/Drp1 Signaling Pathway Mediates Hippocampal Synaptic Damage and Neural Oscillation Abnormalities in a Mouse Model of Sepsis-associated Encephalopathy,” J Neuroinflammation 21, no. 1 (2024): 96.

[88] W. Su, Z. Xie, X. Bai, Z. Li, and X. Liu, “The Absence of Gasdermin D Reduces Nuclear Autophagy in a Cecal Ligation and Puncture-Induced Sepsis-Associated Encephalopathy Mouse Model,” Brain Sci 13, no. 3 (2023): 478.

[89] C. L. Zhu, J. Xie, Q. Liu, et al., “PD-L1 Promotes GSDMD-mediated NET Release by Maintaining the Transcriptional Activity of Stat3 in Sepsis-associated Encephalopathy,” Int J Biol Sci 19, no. 5 (2023): 1413–1429.

[90] X. Huang, C. Ye, X. Zhao, et al., “TRIM45 aggravates Microglia Pyroptosis via Atg5/NLRP3 Axis in Septic Encephalopathy,” J Neuroinflammation 20, no. 1 (2023): 284.

[91] G. Jing, J. Zuo, Q. Fang, et al., “Erbin Protects against Sepsis-associated Encephalopathy by Attenuating Microglia Pyroptosis via IRE1α/Xbp1s-Ca2+ Axis,” J Neuroinflammation 19, no. 1 (2022): 237.

[92] Y. Qin, G. Ge, P. Yang, et al., “An Update on Adipose-Derived Stem Cells for Regenerative Medicine: Where Challenge Meets Opportunity,” Adv Sci (Weinh) 10, no. 20 (2023): e2207334.

[93] Y. Zhan, L. Zhang, J. Sun, H. Yao, J. Chen, and M. Tian, “ADSC-derived Exosomes Provide Neuroprotection in Sepsis-associated Encephalopathy by Regulating Hippocampal Pyroptosis,” Experimental Neurology 380 (2024): 114900.

[94] X. Zhong, Z. Chen, Y. Wang, et al., “JQ1 attenuates Neuroinflammation by Inhibiting the Inflammasome-dependent Canonical Pyroptosis Pathway in SAE,” Brain Research Bulletin 189 (2022): 174–183.

[95] S. Liu, S. Yao, H. Yang, S. Liu, and Y. Wang, “Autophagy: Regulator of Cell Death,” Cell death & disease 14, no. 10 (2023): 648.

[96] L. Zhao, R. An, and Y. Yang, “Melatonin Alleviates Brain Injury in Mice Subjected to Cecal Ligation and Puncture via Attenuating Inflammation, Apoptosis, and Oxidative Stress: The Role of SIRT1 Signaling,” Journal of Pineal Research 59, no. 2 (2015): 230–239.

[97] C. Mai, L. Qiu, Y. Zeng, and H. G. Jian, “LncRNA Lethe Protects Sepsis-induced Brain Injury via Regulating Autophagy of Cortical Neurons,” European Review for Medical and Pharmacological Sciences 23, no. 11 (2019): 4858–4864.

[98] L. Du, Y. Wu, Q. Jia, et al., “Autophagy Suppresses Ferroptosis by Degrading TFR1 to Alleviate Cognitive Dysfunction in Mice with SAE,” Cellular and Molecular Neurobiology 43, no. 7 (2023): 3605–3622.

[99] Y. Li, Z. Fan, Q. Jia, et al., “Chaperone-mediated Autophagy (CMA) Alleviates Cognitive Impairment by Reducing Neuronal Death in Sepsis-associated Encephalopathy (SAE),” Experimental Neurology 365 (2023): 114417.

[100] Y. Lu, Z. Li, S. Zhang, T. Zhang, Y. Liu, and L. Zhang, “Cellular Mitophagy: Mechanism, Roles in Diseases and Small Molecule Pharmacological Regulation,” Theranostics 13, no. 2 (2023): 736–766.

[101] Y. Cui, J. Liu, Y. Song, C. Chen, Y. Shen, and K. Xie, “High Concentration Hydrogen Protects Sepsis-Associated Encephalopathy by Enhancing Pink1/Parkin-Mediated Mitophagy and Inhibiting cGAS-STING-IRF3 Pathway,” CNS neuroscience & therapeutics 31, no. 2 (2025): e70305.

[102] X. Jiang, B. R. Stockwell, and M. Conrad, “Ferroptosis: Mechanisms, Biology and Role in Disease,” Nature Reviews Molecular Cell Biology 22, no. 4 (2021): 266–282.

[103] R. She, D. Liu, J. Liao, G. Wang, J. Ge, and Z. Mei, “Mitochondrial Dysfunctions Induce PANoptosis and Ferroptosis in Cerebral Ischemia/Reperfusion Injury: From Pathology to Therapeutic Potential,” Front Cell Neurosci 17 (2023): 1191629.

[104] H. Y. Tian, B. Y. Huang, H. F. Nie, et al., “The Interplay between Mitochondrial Dysfunction and Ferroptosis during Ischemia-Associated Central Nervous System Diseases,” Brain Sci 13, no. 10 (2023): 1367.

[105] L. Xl, Z. Gy, G. R, and C. N, “Ferroptosis in Sepsis: The Mechanism, the Role and the Therapeutic Potential,” Frontiers in immunology 13 (2022): 956361.

[106] Z. Xie, M. Xu, J. Xie, et al., “Inhibition of Ferroptosis Attenuates Glutamate Excitotoxicity and Nuclear Autophagy in a CLP Septic Mouse Model,” Shock 57, no. 5 (2022): 694–702.

[107] X. B. Wei, W. Q. Jiang, J. H. Zeng, et al., “Exosome-Derived lncRNA NEAT1 Exacerbates Sepsis-Associated Encephalopathy by Promoting Ferroptosis Through Regulating miR-9-5p/TFRC and GOT1 Axis,” Molecular Neurobiology 59, no. 3 (2022): 1954–1969.

[108] H. Wu, N. Li, S. Peng, H. Fu, Z. Hu, and L. Su, “Maresin1 improves Hippocampal Neuroinflammation and Cognitive Function in Septic Rats by Activating the SLC7A11 /GPX4 Ferroptosis Signaling Pathway,” International Immunopharmacology 131 (2024): 111792.

[109] W. M. Lee, “Acetaminophen (APAP) Hepatotoxicity-Isn't It Time for APAP to Go away?,” Journal of Hepatology 67, no. 6 (2017): 1324–1331.

[110] J. Chu, H. Li, Z. Yuan, W. Zhou, Y. Yu, and Y. Yu, “Acetaminophen Impairs Ferroptosis in the Hippocampus of Septic Mice by Regulating Glutathione Peroxidase 4 and Ferroptosis Suppressor Protein 1 Pathways,” Brain Behav 13, no. 8 (2023): e3145.

[111] Y. Zhou, Y. Yang, L. Yi, M. Pan, W. Tang, and H. Duan, “Propofol Mitigates Sepsis-Induced Brain Injury by Inhibiting Ferroptosis via Activation of the Nrf2/HO-1axis,” Neurochemical Research 49, no. 8 (2024): 2131–2147.

[112] J. Wang, Q. Zhu, Y. Wang, J. Peng, L. Shao, and X. Li, “Irisin Protects against Sepsis-associated Encephalopathy by Suppressing Ferroptosis via Activation of the Nrf2/GPX4 Signal Axis,” Free Radic Biol Med 187 (2022): 171–184.

[113] Q. Sun, Q. Liu, X. Zhou, et al., “Flavonoids Regulate Tumor-associated Macrophages—From Structure-activity Relationship to Clinical Potential (Review),” Pharmacological Research 184 (2022): 106419.

[114] H. Zhou, Y. Lai, Y. Zhu, et al., “Quercetin Improves Airway Remodeling in COPD Rats by Suppressing Phenotypic Switch of ASMCs via Inhibiting the Wnt5a/β-catenin Pathway,” Phytomedicine 139 (2025): 156491.

[115] Y. S. Yang, C. Y. Liu, M. Q. Pei, Z. D. Sun, S. Lin, and H. F. He, “Quercetin Protects against Sepsis-associated Encephalopathy by Inhibiting Microglia-neuron Crosstalk via the CXCL2/CXCR2 Signaling Pathway,” Phytomedicine 134 (2024): 155987.

[116] M. Li, Y. Yu, K. Xue, et al., “Genistein Mitigates Senescence of Bone Marrow Mesenchymal Stem Cells via ERRα-mediated Mitochondrial Biogenesis and Mitophagy in Ovariectomized Rats,” Redox Biology 61 (2023): 102649.

[117] B. Shi, M. Chen, Z. Xia, et al., “Genistein Attenuates Neuroinflammation and Oxidative Stress and Improves Cognitive Impairment in a Rat Model of Sepsis-associated Encephalopathy: Potential Role of the Nrf2 Signaling Pathway,” Metabolic Brain Disease 38, no. 1 (2023): 339–347.

[118] Z. Wang, J. Cui, D. Li, S. Ran, J. Huang, and G. Chen, “Morin Exhibits a Neuroprotective Effect in MPTP-induced Parkinson's Disease Model via TFEB/AMPK-mediated Mitophagy,” Phytomedicine 116 (2023): 154866.

[119] A. R. Mohamed, N. H. Fares, and Y. I. Mahmoud, “Morin Ameliorates Lipopolysaccharides-Induced Sepsis-Associated Encephalopathy and Cognitive Impairment in Albino Mice,” Neurochemical Research 50, no. 1 (2024): 14.

[120] S. Jiang, S. Qiu, Y. Mu, et al., “Puerarin Reduces Susceptibility to Ventricular Arrhythmias and Inhibits Ferroptosis via Sirt1/Nrf2 Signaling in High-fat-diet Rats,” Free Radic Biol Med 227 (2025): 472–484.

[121] S. Zhou, Y. Li, Y. Hong, Z. Zhong, and M. Zhao, “Puerarin Protects against Sepsis-associated Encephalopathy by Inhibiting NLRP3/Caspase-1/GSDMD Pyroptosis Pathway and Reducing Blood-brain Barrier Damage,” European Journal of Pharmacology 945 (2023): 175616.

[122] S. P. Lin, L. Zhu, H. Shi, et al., “Puerarin Prevents Sepsis-associated Encephalopathy by Regulating the AKT1 Pathway in Microglia,” Phytomedicine 121 (2023): 155119.

[123] C. C. Chen and W. H. Chan, “Impact Effects of Puerarin on Mouse Embryonic Development,” Reproductive Toxicology 28, no. 4 (2009): 530–535.

[124] P. Saha, G. Saraswat, P. Chakraborty, S. Banerjee, B. C. Pal, and S. N. Kabir, “Puerarin, a Selective Oestrogen Receptor Modulator, Disrupts Pregnancy in Rats at Pre-implantation Stage,” Reproduction 144, no. 5 (2012): 633–645.

[125] Y. Chen, H. Bian, J. Lv, et al., “Gelsevirine Is a Novel STING-specific Inhibitor and Mitigates STING-related Inflammation in Sepsis,” Frontiers in immunology 14 (2023): 1190707.

[126] Q. Q. Zeng, J. Wang, R. C. Yue, et al., “Gelsevirine Ameliorates Sepsis-associated Encephalopathy by Inhibiting the STING Signalling-mediated Pyroptosis Pathway in Microglia,” Phytomedicine 135 (2024): 156071.

[127] L. Wang, J. Wang, L. Han, and T. Chen, “Palmatine Attenuated Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting M1 Phenotype Macrophage Polarization via NAMPT/TLR2/CCR1 Signaling,” Journal of Agricultural and Food Chemistry 72, no. 16 (2024): 9087–9101.

[128] Y. Xu, B. Shen, X. Pan, et al., “Palmatine Ameliorated Lipopolysaccharide-induced Sepsis-associated Encephalopathy Mice by Regulating the Microbiota-gut-brain Axis,” Phytomedicine 124 (2024): 155307.

[129] X. Feng, A. Sureda, S. Jafari, et al., “Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics,” Theranostics 9, no. 7 (2019): 1923–1951.

[130] J. Shi, H. Xu, M. J. Cavagnaro, X. Li, and J. Fang, “Blocking HMGB1/RAGE Signaling by Berberine Alleviates A1 Astrocyte and Attenuates Sepsis-Associated Encephalopathy,” Frontiers in pharmacology 12 (2021): 760186.

[131] H. Gong, Y. Xia, G. Jing, et al., “Berberine Alleviates Neuroinflammation by Downregulating NF-κB/LCN2 Pathway in Sepsis-associated Encephalopathy: Network Pharmacology, Bioinformatics, and Experimental Validation,” International Immunopharmacology 133 (2024): 112036.

[132] X. Zhang, Z. Li, P. Yang, et al., “Polyphenol Scaffolds in Tissue Engineering,” Mater Horiz 8, no. 1 (2021): 145–167.

[133] X. Zheng, Y. Xing, K. Sun, H. Jin, W. Zhao, and F. Yu, “Combination Therapy with Resveratrol and Celastrol Using Folic Acid-Functionalized Exosomes Enhances the Therapeutic Efficacy of Sepsis,” Adv Healthc Mater 12, no. 29 (2023): e2301325.

[134] Y. Chen, R. Luo, J. Li, et al., “Intrinsic Radical Species Scavenging Activities of Tea Polyphenols Nanoparticles Block Pyroptosis in Endotoxin-Induced Sepsis,” ACS Nano 16, no. 2 (2022): 2429–2441.

[135] B. Ren, M. X. Kwah, C. Liu, et al., “Resveratrol for Cancer Therapy: Challenges and Future Perspectives,” Cancer Letters 515 (2021): 63–72.

[136] Y. Yin, G. Lv, W. Zhang, et al., “Resveratrol Glycoside Mediates Microglial Endoplasmic Reticulum Stress to Mitigate LPS-induced Sepsis-associated Cognitive Dysfunction,” Behavioural Brain Research 443 (2023): 114326.

[137] D. M. Sui, Q. Xie, W. J. Yi, et al., “Resveratrol Protects against Sepsis-Associated Encephalopathy and Inhibits the NLRP3/IL-1β Axis in Microglia,” Mediators of Inflammation 2016 (2016): 1045657.

[138] Z. Li, Y. Yu, Y. Bu, et al., “Targeting Macrophagic RasGRP1 with Catechin Hydrate Ameliorates Sepsis-induced Multiorgan Dysfunction,” Phytomedicine 130 (2024): 155733.

[139] L. Huang, J. Chen, X. Li, et al., “Polydatin Improves Sepsis-Associated Encephalopathy by Activating Sirt1 and Reducing p38 Phosphorylation,” Journal of Surgical Research 276 (2022): 379–393.

[140] Y. Liu, X. Yao, Y. Yang, et al., “Americanin B Inhibits Pyroptosis in Lipopolysaccharide-induced Septic Encephalopathy Mice through Targeting NLRP3 Protein,” Phytomedicine 128 (2024): 155520.

[141] J. Ge, Z. Liu, Z. Zhong, et al., “Natural Terpenoids with Anti-inflammatory Activities: Potential Leads for Anti-inflammatory Drug Discovery,” Bioorganic Chemistry 124 (2022): 105817.

[142] C. Junren, X. Xiaofang, L. Mengting, et al., “Pharmacological Activities and Mechanisms of Action of Pogostemon cablin Benth: A Review,” Chinese Medicine 16, no. 1 (2021): 5.

[143] H. Luo, N. Xu, J. Wu, et al., “β-patchoulene Protects against Non-alcoholic Steatohepatitis via Interrupting the Vicious Circle among Oxidative Stress, Histanoxia and Lipid Accumulation in Rats,” International Immunopharmacology 98 (2021): 107915.

[144] Y. Tian, L. Wang, X. Fan, H. Zhang, Z. Dong, and T. Tao, “β-patchoulene Alleviates Cognitive Dysfunction in a Mouse Model of Sepsis Associated Encephalopathy by Inhibition of Microglia Activation through Sirt1/Nrf2 Signaling Pathway,” PLoS ONE 18, no. 1 (2023): e0279964.

[145] L. P. Zhao, H. J. Wang, D. Hu, et al., “β-Elemene Induced Ferroptosis via TFEB-mediated GPX4 Degradation in EGFR Wide-type Non-small Cell Lung Cancer,” Journal of Advanced Research 62 (2024): 257–272.

[146] Q. Zhao, L. Chen, X. Zhang, H. Yang, Y. Li, and P. Li, “β-elemene Promotes Microglial M2-Like Polarization against Ischemic Stroke via AKT/mTOR Signaling Axis-mediated Autophagy,” Chinese Medicine 19, no. 1 (2024): 86.

[147] C. Pan, Y. Si, Q. Meng, et al., “Suppression of the RAC1/MLK3/p38 Signaling Pathway by β-Elemene Alleviates Sepsis-Associated Encephalopathy in Mice,” Frontiers in neuroscience 13 (2019): 358.

[148] S. J. Yang, J. J. Wang, P. Cheng, L. X. Chen, J. M. Hu, and G. Q. Zhu, “Ginsenoside Rg1 in Neurological Diseases: From Bench to Bedside,” Acta Pharmacologica Sinica 44, no. 5 (2023): 913–930.

[149] Y. Chen, M. Chi, X. Qiao, J. Wang, and Y. Jin, “Anti-Inflammatory Effect of Ginsenoside Rg1 on LPS-Induced Septic Encephalopathy and Associated Mechanism,” Curr Neurovasc Res 19, no. 1 (2022): 38–46.

[150] Y. Li, F. Wang, and Y. Luo, “Ginsenoside Rg1 Protects against Sepsis-associated Encephalopathy through Beclin 1-independent Autophagy in Mice,” Journal of Surgical Research 207 (2017): 181–189.

[151] K. Ping, R. Yang, H. Chen, et al., “Gypenoside XLIX Alleviates Intestinal Injury by Inhibiting Sepsis-induced Inflammation, Oxidative Stress, Apoptosis, and Autophagy,” Chemico-Biological Interactions 397 (2024): 111077.

[152] P. Zhao, W. Zhang, X. Zhou, Y. Zhao, A. Li, and Y. Sun, “Gypenoside XLIX Alleviates Sepsis-associated Encephalopathy by Targeting PPAR-α,” Experimental Neurology 383 (2025): 115027.

[153] G. M. Keating, “Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting,” Drugs 75, no. 10 (2015): 1119–1130.

[154] X. Zhang, Y. Feng, Y. Zhong, et al., “Dexmedetomidine Attenuates Neuroinflammation-Mediated Hippocampal Neurogenesis Impairment in Sepsis-Associated Encephalopathy Mice through Central α2A-Adrenoceptor,” Acs Chemical Neuroscience 15, no. 22 (2024): 4185–4201.

[155] Q. Jia, L. Yang, J. Wang, et al., “Dexmedetomidine Improves Sleep Quality and Alleviates Emotional Dysfunction by Attenuating α-synuclein Deposition in Mice with Sepsis-associated Encephalopathy,” Journal of Advanced Research 82 (2026): 331–345.

[156] H. Zhao, Y. Lyu, R. Zhai, G. Sun, and X. Ding, “Metformin Mitigates Sepsis-Related Neuroinflammation via Modulating Gut Microbiota and Metabolites,” Frontiers in immunology 13 (2022): 797312.

[157] Y. Kong, Y. Tai, B. Chen, et al., “A Multi-omics Study of Magnesium Sulfate to Improve Prognosis in Sepsis-related Encephalopathy: Integrating Clinical Data-driven Network Pharmacology,” Frontiers in Cellular and Infection Microbiology 15 (2025): 1607586.

[158] C. F. Rose, P. Amodio, J. S. Bajaj, et al., “Hepatic Encephalopathy: Novel Insights into Classification, Pathophysiology and Therapy,” Journal of Hepatology 73, no. 6 (2020): 1526–1547.

[159] C. Rose, W. Kresse, and H. Kettenmann, “Acute Insult of Ammonia Leads to Calcium-dependent Glutamate Release from Cultured Astrocytes, an Effect of pH,” Journal of Biological Chemistry 280, no. 22 (2005): 20937–20944.

[160] A. Hadjihambi, F. De Chiara, P. S. Hosford, et al., “Ammonia Mediates Cortical Hemichannel Dysfunction in Rodent Models of Chronic Liver Disease,” Hepatology 65, no. 4 (2017): 1306–1318.

[161] I. D. Limón, I. Angulo-Cruz, L. Sánchez-Abdon, and A. Patricio-Martínez, “Disturbance of the Glutamate-Glutamine Cycle, Secondary to Hepatic Damage, Compromises Memory Function,” Frontiers in neuroscience 15 (2021): 578922.

[162] S. Rivera-Mancía, L. Tristán-López, K. Hernández-Díaz, L. Rivera-Espinosa, C. Ríos, and S. Montes, “In Vitro Inhibition of Brain Phosphate-activated Glutaminase by Ammonia and Manganese,” Journal of Trace Elements in Medicine and Biology 62 (2020): 126625.

[163] S. Dhanda, A. Sunkaria, A. Halder, and R. Sandhir, “Mitochondrial Dysfunctions Contribute to Energy Deficits in Rodent Model of Hepatic Encephalopathy,” Metabolic Brain Disease 33, no. 1 (2018): 209–223.

[164] P. R. Angelova, A. J. C. Kerbert, A. Habtesion, A. Hall, A. Y. Abramov, and R. Jalan, “Hyperammonaemia Induces Mitochondrial Dysfunction and Neuronal Cell Death,” JHEP Rep 4, no. 8 (2022): 100510.

[165] R. A. Waniewski, “Physiological Levels of Ammonia Regulate Glutamine Synthesis from Extracellular Glutamate in Astrocyte Cultures,” Journal of Neurochemistry 58, no. 1 (1992): 167–174.

[166] J. Albrecht, U. Wysmyk-Cybula, and U. Rafalowska, “Na+/K+-ATPase Activity and GABA Uptake in Astroglial Cell-enriched Fractions and Synaptosomes Derived from Rats in the Early Stage of Experimental Hepatogenic Encephalopathy,” Acta Neurologica Scandinavica 72, no. 3 (1985): 317–320.

[167] R. Heidari, “Brain Mitochondria as Potential Therapeutic Targets for Managing Hepatic Encephalopathy,” Life Sciences 218 (2019): 65–80.

[168] C. R. Murthy, K. V. Rama Rao, G. Bai, and M. D. Norenberg, “Ammonia-induced Production of Free Radicals in Primary Cultures of Rat Astrocytes,” Journal of Neuroscience Research 66, no. 2 (2001): 282–288.

[169] O. Braissant, V. Rackayová, K. Pierzchala, J. Grosse, V. A. McLin, and C. Cudalbu, “Longitudinal Neurometabolic Changes in the Hippocampus of a Rat Model of Chronic Hepatic Encephalopathy,” Journal of Hepatology 71, no. 3 (2019): 505–515.

[170] F. Tamnanloo, R. Ochoa-Sanchez, M. M. Oliveira, et al., “Multiple Ammonia-induced Episodes of Hepatic Encephalopathy Provoke Neuronal Cell Loss in Bile-duct Ligated Rats,” JHEP Rep 5, no. 12 (2023): 100904.

[171] O. Braissant, “Current Concepts in the Pathogenesis of Urea Cycle Disorders,” Molecular Genetics and Metabolism 100, no. Suppl 1 (2010): S3–S12.

[172] M. Llansola, R. Rodrigo, P. Monfort, et al., “NMDA Receptors in Hyperammonemia and Hepatic Encephalopathy,” Metabolic Brain Disease 22, no. 3-4 (2007): 321–335.

[173] R. Rodrigo, O. Cauli, J. Boix, N. ElMlili, A. Agusti, and V. Felipo, “Role of NMDA Receptors in Acute Liver Failure and Ammonia Toxicity: Therapeutical Implications,” Neurochemistry International 55, no. 1-3 (2009): 113–118.

[174] E. A. Jones, “Ammonia, the GABA Neurotransmitter System, and Hepatic Encephalopathy,” Metabolic Brain Disease 17, no. 4 (2002): 275–281.

[175] R. Leke, L. K. Bak, P. Iversen, et al., “Synthesis of Neurotransmitter GABA via the Neuronal Tricarboxylic Acid Cycle Is Elevated in Rats with Liver Cirrhosis Consistent with a High GABAergic Tone in Chronic Hepatic Encephalopathy,” Journal of Neurochemistry 117, no. 5 (2011): 824–832.

[176] O. Cauli, M. T. Mansouri, A. Agusti, and V. Felipo, “Hyperammonemia Increases GABAergic Tone in the Cerebellum but Decreases It in the Rat Cortex,” Gastroenterology 136, no. 4 (2009): 1359. e2.

[177] V. Hernández-Rabaza, A. Cabrera-Pastor, L. Taoro-González, et al., “Hyperammonemia Induces Glial Activation, Neuroinflammation and Alters Neurotransmitter Receptors in Hippocampus, Impairing Spatial Learning: Reversal by Sulforaphane,” J Neuroinflammation 13 (2016): 41.

[178] M. Skowrońska and J. Albrecht, “Alterations of Blood Brain Barrier Function in Hyperammonemia: An Overview,” Neurotoxicity Research 21, no. 2 (2012): 236–244.

[179] Y. M. Arenas, C. Montoliu, M. Llansola, and V. Felipo, “A Transient Blood IL-17 Increase Triggers Neuroinflammation in Cerebellum and Motor Incoordination in Hyperammonemic Rats,” J Neuroinflammation 21, no. 1 (2024): 314.

[180] A. Cabrera-Pastor, M. Llansola, C. Montoliu, et al., “Peripheral Inflammation Induces Neuroinflammation That Alters Neurotransmission and Cognitive and Motor Function in Hepatic Encephalopathy: Underlying Mechanisms and Therapeutic Implications,” Acta Physiol (Oxf) 226, no. 2 (2019): e13270.

[181] E. Manzhalii, O. Virchenko, T. Falalyeyeva, et al., “Hepatic Encephalopathy Aggravated by Systemic Inflammation,” Digestive Diseases 37, no. 6 (2019): 509–517.

[182] Y. M. Arenas, A. López-Gramaje, C. Montoliu, M. Llansola, and V. Felipo, “Increased Levels and Activation of the IL-17 Receptor in Microglia Contribute to Enhanced Neuroinflammation in Cerebellum of Hyperammonemic Rats,” Biological Research 57, no. 1 (2024): 18.

[183] P. Izquierdo-Altarejos, M. Martínez-García, and V. Felipo, “Extracellular Vesicles from Hyperammonemic Rats Induce Neuroinflammation in Hippocampus and Impair Cognition in Control Rats,” Cellular and Molecular Life Sciences 80, no. 4 (2023): 90.

[184] D. Gandhi, A. P. Rudrashetti, and S. Rajasekaran, “The Impact of Environmental and Occupational Exposures of Manganese on Pulmonary, Hepatic, and Renal Functions,” Journal of Applied Toxicology 42, no. 1 (2022): 103–129.

[185] L. Abenavoli, G. Fabiano, A. C. Procopio, et al., “Hepatic Encephalopathy by Manganese Deposition: A Case Report and a Review of Literature,” Rev Recent Clin Trials 17, no. 3 (2022): 216–219.

[186] S. Bouabid, A. Tinakoua, N. Lakhdar-Ghazal, and A. Benazzouz, “Manganese Neurotoxicity: Behavioral Disorders Associated with Dysfunctions in the Basal Ganglia and Neurochemical Transmission,” Journal of Neurochemistry 136, no. 4 (2016): 677–691.

[187] J. Johnson, E. A. B. Pajarillo, E. Taka, et al., “Valproate and Sodium Butyrate Attenuate Manganese-decreased Locomotor Activity and Astrocytic Glutamate Transporters Expression in Mice,” Neurotoxicology 64 (2018): 230–239.

[188] I. Nyarko-Danquah, E. Pajarillo, A. Digman, K. F. A. Soliman, M. Aschner, and E. Lee, “Manganese Accumulation in the Brain via Various Transporters and Its Neurotoxicity Mechanisms,” Molecules 25, no. 24 (2020): 5880, Published 2020 Dec 12.

[189] K. V. Rama Rao, P. V. Reddy, A. S. Hazell, and M. D. Norenberg, “Manganese Induces Cell Swelling in Cultured Astrocytes,” Neurotoxicology 28, no. 4 (2007): 807–812.

[190] V. Tripodi, M. Contin, M. A. Fernández, and A. Lemberg, “Bile Acids Content in Brain of Common Duct Ligated Rats,” Annals of Hepatology 11, no. 6 (2012): 930–934.

[191] M. McMillin, G. Frampton, S. Grant, et al., “Bile Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Promotes Neuroinflammation during Hepatic Encephalopathy in Mice,” Front Cell Neurosci 11 (2017): 191.

[192] C. Ren, L. Cha, S. Y. Huang, et al., “Dysregulation of Bile Acid Signal Transduction Causes Neurological Dysfunction in Cirrhosis Rats,” World J Hepatol 17, no. 3 (2025): 101340.

[193] H. Zhi, Z. Wang, X. Zhu, et al., “Chronic Liver Injury Decreases Levels of Cerebral Carnitine and Acetylcarnitine in Rats Partly due to the Downregulation of Organic Cation Transporters OCT1/2 and OCTN2 at the Blood-brain Barrier,” Drug Metabolism and Disposition 53, no. 5 (2025): 100072.

[194] P. A. Guazzelli, F. D. S. Fachim, A. S. Travassos, et al., “Glutamine and Albumin Levels in Cerebrospinal Fluid Are Correlated with Neurological Severity in an Experimental Model of Acute Hepatic Encephalopathy,” Metabolites 15, no. 9 (2025): 598.

[195] S. M. Eraky, D. H. El-Kashef, M. El-Sherbiny, and N. F. Abo El-Magd, “Naringenin Mitigates Thioacetamide-induced Hepatic Encephalopathy in Rats: Targeting the JNK/Bax/Caspase-8 Apoptotic Pathway,” Food Funct 14, no. 2 (2023): 1248–1258.

[196] N. F. Abo El-Magd, D. H. El-Kashef, M. El-Sherbiny, and S. M. Eraky, “Hepatoprotective and Cognitive-enhancing Effects of Hesperidin against Thioacetamide-induced Hepatic Encephalopathy in Rats,” Life Sciences 313 (2023): 121280.

[197] F. Frozandeh, N. Shahrokhi, M. Khaksari, et al., “Evaluation of the Protective Effect of Curcumin on Encephalopathy Caused by Intrahepatic and Extrahepatic Damage in Male Rats,” Iran J Basic Med Sci 24, no. 6 (2021): 760–766.

[198] U. Okkay, I. Ferah Okkay, B. Cicek, I. C. Aydin, and M. Ozkaraca, “Hepatoprotective and Neuroprotective Effect of Taxifolin on Hepatic Encephalopathy in Rats,” Metabolic Brain Disease 37, no. 5 (2022): 1541–1556.

[199] M. Kaboutari, M. Asle-Rousta, and S. Mahmazi, “Protective Effect of Menthol against Thioacetamide-induced Hepatic Encephalopathy by Suppressing Oxidative Stress and Inflammation, Augmenting Expression of BDNF and α7-nACh Receptor, and Improving Spatial Memory,” European Journal of Pharmacology 981 (2024): 176916.

[200] S. A. Ali and A. K. Datusalia, “Berberine Inhibits the Disruption of the Blood-Brain Barrier and Glial Cell Activation in a Rat Model of Acute Hepatic Encephalopathy,” Phytotherapy Research 39, no. 3 (2025): 1422–1437.

[201] S. Hajipour, Y. Farbood, M. Dianat, A. Nesari, and A. Sarkaki, “Effect of Berberine against Cognitive Deficits in Rat Model of Thioacetamide-Induced Liver Cirrhosis and Hepatic Encephalopathy (Behavioral, Biochemical, Molecular and Histological Evaluations),” Brain Sci 13, no. 6 (2023): 944.

[202] J. Yin, H. Xing, and J. Ye, “Efficacy of Berberine in Patients with Type 2 Diabetes Mellitus,” Metabolism 57, no. 5 (2008): 712–717.

[203] H. Li, Y. Xiang, Z. Zhu, et al., “Rifaximin-mediated Gut Microbiota Regulation Modulates the Function of Microglia and Protects against CUMS-induced Depression-Like Behaviors in Adolescent Rat,” J Neuroinflammation 18, no. 1 (2021): 254.

[204] P. Leone, G. Mincheva, T. Balzano, M. Malaguarnera, V. Felipo, and M. Llansola, “Rifaximin Improves Spatial Learning and Memory Impairment in Rats with Liver Damage-Associated Neuroinflammation,” Biomedicines 10, no. 6 (2022): 1263.

[205] X. Lin, Z. Zhang, Y. Lin, S. Lu, and R. Chen, “The Effects of Rifaximin and Lactulose on the Gut-liver-brain Axis in Rats with Minimal Hepatic Encephalopathy,” PLoS ONE 20, no. 6 (2025): e0325988.

[206] Y. Zhang, S. L. Tan, J. Du, et al., “Dexmedetomidine Alleviates Neuroinflammation, Restores Sleep Disorders and Neurobehavioral Abnormalities in Rats with Minimal Hepatic Encephalopathy,” International Immunopharmacology 96 (2021): 107795.

[207] T. Paljarvi, J. Forton, S. Luciano, K. Herttua, and S. Fazel, “Analysis of Neuropsychiatric Diagnoses After Montelukast Initiation,” JAMA Network Open 5, no. 5 (2022): e2213643.

[208] R. S. Abdelrahman, R. R. Abdelaziz, and M. E. Abdelmageed, “Montelukast Alleviates Thioacetamide-induced Hepatic Encephalopathy in Rats,” Naunyn-Schmiedebergs Archives of Pharmacology 398, no. 11 (2025): 16019–16030.

[209] N. F. Hassan, M. R. El-Ansary, A. R. El-Ansary, M. A. El-Saied, and O. S. Zaki, “Unveiling the Protective Potential of Mirabegron against Thioacetamide-induced Hepatic Encephalopathy in Rats: Insights into cAMP/PPAR-γ/p-ERK1/2/p S536 NF-κB p 65 and p-CREB/BDNF/TrkB in Parallel with Oxidative and Apoptotic Trajectories,” Biochemical Pharmacology 229 (2024): 116504.

[210] E. K. Mohamed and D. M. Hafez, “Gallic Acid and Metformin co-administration Reduce Oxidative Stress, Apoptosis and Inflammation via Fas/Caspase-3 and NF-κB Signaling Pathways in Thioacetamide-induced Acute Hepatic Encephalopathy in Rats,” BMC Complement Med Ther 23, no. 1 (2023): 265.

[211] M. Douglas-Escobar and M. D. Weiss, “Hypoxic-ischemic Encephalopathy: A Review for the Clinician,” JAMA Pediatr 169, no. 4 (2015): 397–403.

[212] H. R. Chen, C. W. Chen, Y. M. Kuo, et al., “Monocytes Promote Acute Neuroinflammation and Become Pathological Microglia in Neonatal Hypoxic-ischemic Brain Injury,” Theranostics 12, no. 2 (2022): 512–529.

[213] A. S. Bremer, N. Henschel, H. Burkard, M. E. Bernis, T. Ulas, and H. Sabir, “Transcriptomic Profile of Microglia Following Inflammation-sensitized Hypoxic-ischemic Brain Injury in Neonatal Rats Suggests Strong Contribution to Neutrophil Chemotaxis and Activation,” J Neuroinflammation 22, no. 1 (2025): 189.

[214] L. Yang, Y. Zhang, X. Yu, et al., “Periventricular Microglia Polarization and Morphological Changes Accompany NLRP3 Inflammasome-Mediated Neuroinflammation after Hypoxic-Ischemic White Matter Damage in Premature Rats,” Journal of Immunology Research 2023 (2023): 5149306.

[215] X. L. Yang, X. Wang, L. Shao, et al., “TRPV1 mediates Astrocyte Activation and Interleukin-1β Release Induced by Hypoxic Ischemia (HI),” J Neuroinflammation 16, no. 1 (2019): 114.

[216] A. Drobyshevsky, S. Synowiec, I. Goussakov, R. Fabres, J. Lu, and M. Caplan, “Intestinal Microbiota Modulates Neuroinflammatory Response and Brain Injury after Neonatal Hypoxia-ischemia,” Gut Microbes 16, no. 1 (2024): 2333808.

[217] A. Chen, C. Teng, J. Wei, et al., “Gut Microbial Dysbiosis Exacerbates Long-term Cognitive Impairments by Promoting Intestinal Dysfunction and Neuroinflammation Following Neonatal Hypoxia-ischemia,” Gut Microbes 17, no. 1 (2025): 2471015.

[218] K. Zhu, X. Zhu, S. Sun, et al., “Inhibition of TLR4 Prevents Hippocampal Hypoxic-ischemic Injury by Regulating Ferroptosis in Neonatal Rats,” Experimental Neurology 345 (2021): 113828.

[219] M. Fang, Q. Yu, J. Ou, J. Lou, J. Zhu, and Z. Lin, “The Neuroprotective Mechanisms of PPAR-γ: Inhibition of Microglia-Mediated Neuroinflammation and Oxidative Stress in a Neonatal Mouse Model of Hypoxic-Ischemic White Matter Injury,” CNS neuroscience & therapeutics 30, no. 11 (2024): e70081.

[220] M. Rodríguez, V. Valez, C. Cimarra, F. Blasina, and R. Radi, “Hypoxic-Ischemic Encephalopathy and Mitochondrial Dysfunction: Facts, Unknowns, and Challenges,” Antioxid Redox Signaling 33, no. 4 (2020): 247–262.

[221] S. Hu, Y. Lopez-Robles, G. Shen, E. Liu, L. Zhang, and Q. Ma, “MicroRNA210 Suppresses Mitochondrial Metabolism and Promotes Microglial Activation in Neonatal Hypoxic-Ischemic Brain Injury,” Cells 14, no. 15 (2025): 1202.

[222] F. K. Odorcyk, R. T. Ribeiro, A. C. Roginski, et al., “Differential Age-Dependent Mitochondrial Dysfunction, Oxidative Stress, and Apoptosis Induced by Neonatal Hypoxia-Ischemia in the Immature Rat Brain,” Molecular Neurobiology 58, no. 5 (2021): 2297–2308.

[223] D. N. Silachev, E. Y. Plotnikov, I. B. Pevzner, et al., “Neuroprotective Effects of Mitochondria-Targeted Plastoquinone in a Rat Model of Neonatal Hypoxic⁻Ischemic Brain Injury,” Molecules 23, no. 8 (2018): 1871.

[224] Y. Zhao, C. Gai, S. Yu, et al., “Liposomes-Loaded miR-9-5p Alleviated Hypoxia-Ischemia-Induced Mitochondrial Oxidative Stress by Targeting ZBTB20 to Inhibiting Nrf2/Keap1 Interaction in Neonatal Mice,” Antioxid Redox Signaling 42, no. 10-12 (2025): 512–528.

[225] X. X. Wang, M. Li, X. W. Xu, et al., “BNIP3-mediated Mitophagy Attenuates Hypoxic-ischemic Brain Damage in Neonatal Rats by Inhibiting Ferroptosis through P62-KEAP1-NRF2 Pathway Activation to Maintain Iron and Redox Homeostasis,” Acta Pharmacologica Sinica 46, no. 1 (2025): 33–51.

[226] C. Qin, Y. Li, M. Cheng, et al., “Identifying Pyroptosis-hub Genes and Immune Infiltration in Neonatal Hypoxic-ischemic Brain Injury,” Frontiers in immunology 16 (2025): 1616312.

[227] Y. Lv, B. Sun, X. X. Lu, et al., “The Role of Microglia Mediated Pyroptosis in Neonatal Hypoxic-ischemic Brain Damage,” Biochemical and Biophysical Research Communications 521, no. 4 (2020): 933–938.

[228] Q. Li, Z. Wang, F. Li, et al., “AIM2 exacerbates Hypoxic-ischemic Brain Damage in Neonatal Rats via Promoting Neuronal Pyroptosis,” Brain Research Bulletin 224 (2025): 111305.

[229] S. Sha, N. Jin, R. Zhou, Y. Ruan, and Y. Ouyang, “The Activation of PKM2 Induces Pyroptosis in Hippocampal Neurons via the NLRP3/Caspase-1/GSDMD Pathway in Neonatal Rats With Hypoxic-Ischemic Brain Injury,” Brain Behav 14, no. 10 (2024): e70108.

[230] H. Shen, H. Lu, L. Mao, and L. Song, “Inhibition of cGAS Attenuates Neonatal Hypoxic-ischemic Encephalopathy via Regulating Microglia Polarization and Pyroptosis,” Transl Pediatr 13, no. 8 (2024): 1378–1394.

[231] T. Yu, L. Q. Kui, and Q. Z. Ming, “Effect of Asphyxia on Non-protein-bound Iron and Lipid Peroxidation in Newborn Infants,” Developmental Medicine and Child Neurology 45, no. 1 (2003): 24–27.

[232] M. Yang, K. Wang, B. Liu, Y. Shen, and G. Liu, “Hypoxic-Ischemic Encephalopathy: Pathogenesis and Promising Therapies,” Molecular Neurobiology 62, no. 2 (2025): 2105–2122.

[233] H. Chen, J. Zhao, Y. Kang, et al., “PFGA12 ameliorates Hypoxic-Ischemic Brain Injury by Directly Regulating PRDX1 and Inhibiting Ferroptosis,” Biochemical Pharmacology 242, no. Pt 2 (2025): 117307.

[234] X. He, S. Wei, Y. Fu, H. Li, J. Zhang, and L. Liu, “Nuclear Protein 1 Protects against Neonatal Hypoxic-ischemic Encephalopathy by Inhibiting Neuronal Ferroptosis by Improving Iron Storage,” In Vitro Cellular & Developmental Biology Animal 61, no. 8 (2025): 977–990.

[235] X. Tao, Y. Hu, N. Mao, et al., “Echinatin Alleviates Inflammation and Pyroptosis in Hypoxic-ischemic Brain Damage by Inhibiting TLR4/NF-κB Pathway,” International Immunopharmacology 136 (2024): 112372.

[236] T. Chen, Y. Hu, L. Lu, et al., “Myricetin Attenuates Hypoxic-ischemic Brain Damage in Neonatal Rats via NRF2 Signaling Pathway,” Frontiers in pharmacology 14 (2023): 1134464.

[237] Y. Zhou, Y. Wang, X. Wu, J. Wu, J. Yan, and W. Su, “Carthamin Yellow Attenuates Brain Injury in a Neonatal Rat Model of Ischemic-hypoxic Encephalopathy by Inhibiting Neuronal Ferroptosis in the Hippocampus,” Transl Neurosci 14, no. 1 (2023): 20220331.

[238] J. Lin, L. Deng, A. Qi, et al., “Catalpol Alleviates Hypoxia Ischemia-induced Brain Damage by Inhibiting Ferroptosis through the PI3K/NRF2/System Xc-/GPX4 Axis in Neonatal Rats,” European Journal of Pharmacology 968 (2024): 176406.

[239] S. Bakhtazad, Z. Ghotbeddin, M. R. Tabandeh, and K. Rahimi, “Alpha-pinene Ameliorate Behavioral Deficit Induced by Early Postnatal Hypoxia in the Rat: Study the Inflammatory Mechanism,” Scientific Reports 14, no. 1 (2024): 6416.

[240] Y. Fang, Y. Zheng, Q. Gao, et al., “Activation of the Nrf2/Keap1 Signaling Pathway Mediates the Neuroprotective Effect of Perillyl Alcohol against Cerebral Hypoxic-ischemic Damage in Neonatal Rats,” Redox Report: Communications in Free Radical Research 29, no. 1 (2024): 2394714.

[241] Y. Zheng, L. Li, B. Chen, et al., “Chlorogenic Acid Exerts Neuroprotective Effect against Hypoxia-ischemia Brain Injury in Neonatal Rats by Activating Sirt1 to Regulate the Nrf2-NF-κB Signaling Pathway,” Cell Communication and Signaling 20, no. 1 (2022): 84. P.

[242] C. Dai, X. Li, Z. Dong, et al., “Neuroprotective Effect of Salvianolic Acid C in Neonatal Rats Following Hypoxic-ischemic Brain Damage,” Molecular Neurobiology 62, no. 10 (2025): 13363–13378.

[243] X. Zhang, J. Luo, L. Bharati, Z. Hua, S. Chen, and Z. Dong, “Protocatechuic Acid Suppresses Ferroptosis to Protect against Hypoxic-ischemic Encephalopathy by Targeting the HIF-1α/VEGFA Axis,” Phytomedicine 143 (2025): 156900.

[244] X. Dong, S. Luo, D. Hu, et al., “Gallic Acid Inhibits Neuroinflammation and Reduces Neonatal Hypoxic-ischemic Brain Damages,” Front Pediatr 10 (2022): 973256.

[245] M. Shen, J. Lu, C. Li, et al., “Punicalagin Inhibits Excessive Autophagy and Improves Cerebral Function in Neonatal Rats with Hypoxia-ischemia Brain Injury by Regulating AKT-FOXO4,” Phytomedicine 136 (2025): 156330.

[246] Y. Li, Q. Ye, W. Lu, et al., “Melatonin Enhances Aquaporin 4 and Alpha-Syntrophin Interaction by Inhibiting Cyclin-Dependent Kinase 5 Activity to Preserve Glymphatic Function in Neonatal Hypoxic-Ischemic Encephalopathy,” Journal of Pineal Research 77, no. 4 (2025): e70063.

[247] A. Mohammadi, W. Balduini, and S. Carloni, “Melatonin Modulates the Notch1 Signaling Pathway and Sirt3 in the Hippocampus of Hypoxic-ischemic Neonatal Rats,” Scientific Reports 14, no. 1 (2024): 25069.

[248] T. Cheng, S. Du, Y. Cao, Z. Lu, and Y. Xu, “Neuroprotection in Neonatal Hypoxia-ischaemia: Melatonin Targets NCX1 to Inhibit Mitochondrial Autophagy via the PINK1-Parkin Pathway,” Journal of Molecular Histology 56, no. 5 (2025): 313.

[249] E. Nacarkucuk, M. E. Bernis, A. S. Bremer, et al., “Neuroprotective Effect of Melatonin in a Neonatal Hypoxia-Ischemia Rat Model Is Regulated by the AMPK/mTOR Pathway,” Journal of the American Heart Association 13, no. 19 (2024): e036054.

[250] M. Chillida, F. J. Alvarez, B. H. de la Parte, A. Catalan, A. Alvarez, and D. Alonso-Alconada, “Neuroprotective Effect of the Combination Therapy of Melatonin and URB447 after Neonatal Hypoxia-ischemia,” BMC Complement Med Ther 25, no. 1 (2025): 274.

[251] X. Chen, A. Chen, J. Wei, et al., “Dexmedetomidine Alleviates Cognitive Impairment by Promoting Hippocampal Neurogenesis via BDNF/TrkB/CREB Signaling Pathway in Hypoxic-ischemic Neonatal Rats,” CNS neuroscience & therapeutics 30, no. 1 (2024): e14486.

[252] H. Xue, Z. Ding, X. Chen, et al., “Dexmedetomidine Improves Long-term Neurological Outcomes by Promoting Oligodendrocyte Genesis and Myelination in Neonatal Rats Following Hypoxic-ischemic Brain Injury,” Molecular Neurobiology 62, no. 4 (2025): 4866–4880.

[253] Y. Zhong, S. Wang, Y. Yin, J. Yu, Y. Liu, and H. Gao, “Dexmedetomidine Suppresses Hippocampal Astrocyte Pyroptosis in Cerebral Hypoxic-ischemic Neonatal Rats by Upregulating microRNA-148a-3p to Inactivate the STAT/JMJD3 Axis,” International Immunopharmacology 121 (2023): 110440.

[254] L. Yu, S. Liu, R. Zhou, et al., “Atorvastatin Inhibits Neuronal Apoptosis via Activating cAMP/PKA/p-CREB/BDNF Pathway in Hypoxic-ischemic Neonatal Rats,” Faseb Journal 36, no. 4 (2022): e22263.

[255] L. Yu, L. Huang, Y. Zhao, et al., “Atorvastatin Promotes Pro/Anti-inflammatory Phenotypic Transformation of Microglia via Wnt/β-catenin Pathway in Hypoxic-Ischemic Neonatal Rats,” Molecular Neurobiology 61, no. 6 (2024): 3559–3577.

[256] Q. Ye, W. Lu, T. Li, et al., “Edaravone Attenuates Cerebral Inflammation by Inhibiting Mast Cells Degranulation via ROS/STIM1 Signaling Pathway in HIE Model,” International Immunopharmacology 159 (2025): 114880.

[257] Y. Xu, C. Huang, Y. Zhang, et al., “Diabetic Encephalopathy Models: A Systematic Review from Cells to Animals,” Experimental Neurology 395 (2025): 115477.

[258] Y. Luo, J. Zhu, Z. Hu, et al., “Progress in the Pathogenesis of Diabetic Encephalopathy: The Key Role of Neuroinflammation,” Diabetes Metabolism Research and Reviews 40, no. 6 (2024): e3841.

[259] S. Ma, W. Bi, X. Liu, et al., “Single-Cell Sequencing Analysis of the db/db Mouse Hippocampus Reveals Cell-Type-Specific Insights Into the Pathobiology of Diabetes-Associated Cognitive Dysfunction,” Front Endocrinol (Lausanne) 13 (2022): 891039.

[260] S. X. Yu, H. D. Yu, Y. F. Wang, et al., “Th22 cells Promote the Transition from Homeostatic to Reactive Microglia in Diabetic Encephalopathy,” Acta Diabetologica 62, no. 5 (2025): 633–650.

[261] X. X. Fang, F. F. Xu, Z. Liu, B. B. Cao, Y. H. Qiu, and Y. P. Peng, “Interleukin 17A Deficiency Alleviates Neuroinflammation and Cognitive Impairment in an Experimental Model of Diabetic Encephalopathy,” Neural Regen Res 17, no. 12 (2022): 2771–2777.

[262] T. Xu, J. Liu, X. R. Li, et al., “The mTOR/NF-κB Pathway Mediates Neuroinflammation and Synaptic Plasticity in Diabetic Encephalopathy,” Molecular Neurobiology 58, no. 8 (2021): 3848–3862.

[263] Y. Zhou, J. X. Kou, K. Zheng, et al., “Epigenetic Regulation of DAPK1 and Netrin-1 Drives Diabetic Encephalopathy,” Adv Sci (Weinh) 12, no. 37 (2025): e02535.

[264] Q. Xiang, J. S. Tao, S. Dong, et al., “Heterogeneity and Synaptic Plasticity Analysis of Hippocampus Based on db-/- mice Induced Diabetic Encephalopathy,” Psychoneuroendocrinology 159 (2024): 106412.

[265] Q. Xiang, H. Lin, J. S. Tao, et al., “MiR-18a-LncRNA NONRATG-022419 Pairs Targeted PRG-1 Regulates Diabetic Induced Cognitive Impairment by Regulating NGF∖BDNF-Trkb Signaling Pathway,” Proteome Science 23, no. 1 (2025): 1.

[266] I. R. Baduini, J. E. Castro Vildosola, and S. Kavehmoghaddam, “Type 2 Diabetes Mellitus and Neurodegenerative Disorders: The Mitochondrial Connection,” Pharmacological Research 209 (2024): 107439.

[267] M. Eslami Gharaati, A. Nahavandi, T. Baluchnejad Mojarad, and M. Roghani, “Diabetic Encephalopathy Affecting Mitochondria and Axonal Transport Proteins,” Basic Clin Neurosci 11, no. 6 (2020): 781–793.

[268] S. Yan, F. Du, L. Wu, et al., “F1F0 ATP Synthase-Cyclophilin D Interaction Contributes to Diabetes-Induced Synaptic Dysfunction and Cognitive Decline,” Diabetes 65, no. 11 (2016): 3482–3494.

[269] S. Huang, M. Hua, W. Liu, et al., “Phosphatidate Phosphatase Lipin1 Alters Mitochondria-associated Endoplasmic Reticulum Membranes (MAMs) Homeostasis: Effects Which Contribute to the Development of Diabetic Encephalopathy,” J Neuroinflammation 22, no. 1 (2025): 111.

[270] Z. Zhuang, S. Huang, X. Zhang, et al., “Lipin1 ameliorates Cognitive Ability of Diabetic Encephalopathy via Regulating Ca2+ Transfer through Mitochondria-associated Endoplasmic Reticulum Membranes,” International Immunopharmacology 150 (2025): 114266.

[271] T. Hu, X. Y. Lu, J. J. Shi, et al., “Quercetin Protects against Diabetic Encephalopathy via SIRT1/NLRP3 Pathway in db/db Mice,” Journal of Cellular and Molecular Medicine 24, no. 6 (2020): 3449–3459.

[272] Y. Zhang, S. Zhang, H. Niu, et al., “Metabolite-Based Network Pharmacology, Molecular Docking, and Dynamics Simulations to Preliminarily Verify Treating Diabetic Encephalopathy Effect of Kuwanon G,” Food Sci Nutr 13, no. 6 (2025): e70392.

[273] Y. S. Shi, J. C. Chen, L. Lin, et al., “Dendrobine Rescues Cognitive Dysfunction in Diabetic Encephalopathy by Inhibiting Ferroptosis via Activating Nrf2/GPX4 Axis,” Phytomedicine 119 (2023): 154993.

[274] Z. Li, Y. Zhang, R. Su, et al., “Notoginsenoside R1, a Novel Natural PPARγ Agonist, Attenuates Cognitive Deficits in a Mouse Model of Diabetic Alzheimer's Disease Through Enhancing GLUT4-Dependent Neuronal Glucose Uptake,” Phytotherapy Research 39, no. 12 (2025): 5634–5651.

[275] X. D. Yan, R. H. Fan, Y. Wang, et al., “α-asarone Activates Mitophagy to Relieve Diabetic Encephalopathy via Inhibiting Apoptosis and Oxidative Stress,” Metabolic Brain Disease 40, no. 2 (2025): 126.

[276] Y. Cao, W. Sun, C. Liu, et al., “Resveratrol Ameliorates Diabetic Encephalopathy through PDE4D/PKA/Drp1 Signaling,” Brain Research Bulletin 203 (2023): 110763.

[277] X. H. Wang, Z. F. Zuo, L. Meng, et al., “Neuroprotective Effect of Salidroside on Hippocampal Neurons in Diabetic Mice via PI3K/Akt/GSK-3β Signaling Pathway,” Psychopharmacology (Berl) 240, no. 9 (2023): 1865–1876.

[278] T. Ye, X. Meng, R. Wang, et al., “Gastrodin Alleviates Cognitive Dysfunction and Depressive-Like Behaviors by Inhibiting ER Stress and NLRP3 Inflammasome Activation in db/db Mice,” International Journal of Molecular Sciences 19, no. 12 (2018): 3977.

[279] T. E. LaMoia and G. I. Shulman, “Cellular and Molecular Mechanisms of Metformin Action,” Endocrine Reviews 42, no. 1 (2021): 77–96.

[280] J. L. Chen, C. Luo, D. Pu, et al., “Metformin Attenuates Diabetes-induced Tau Hyperphosphorylation in Vitro and in Vivo by Enhancing Autophagic Clearance,” Experimental Neurology 311 (2019): 44–56.

[281] A. F. Alrefaei and M. E. Elbeeh, “Alpha-Lipoic Acid and Metformin Combination Therapy Synergistically Activate Nrf2-AMPK Signaling Pathways to Ameliorate Cognitive Dysfunction in Type 2 Diabetic Encephalopathy: A Preclinical Study,” Biology (Basel) 14, no. 7 (2025): 885.

[282] M. Salman, H. Shahzad, R. Gangaraju, and T. Ishrat, “Fasudil Mitigates Diabetes-associated Cognitive Decline and Enhances Neuroprotection by Suppressing NLRP3/Caspase-1/GSDMD Signaling in a Stroke Mouse Model,” Experimental Neurology 389 (2025): 115268.

[283] Q. Wu, J. Dong, X. Bai, et al., “Propionate Ameliorates Diabetes-induced Neurological Dysfunction through Regulating the PI3K/Akt/eNOS Signaling Pathway,” European Journal of Pharmacology 925 (2022): 174974.

[284] M. M. Al-Ashram, M. A. Nader, and A. R. El-Sheakh, “Role of Sacubitril/Valsartan in Modulating Diabetes Mediated Cognitive and Neuronal Impairment,” International Immunopharmacology 154 (2025): 114431.

[285] X. Li, P. Yu, Y. Yu, et al., “Hydrogen Sulfide Ameliorates High Glucose-induced Pro-inflammation Factors in HT-22 Cells: Involvement of SIRT1-mTOR/NF-κB Signaling Pathway,” International Immunopharmacology 95 (2021): 107545.

[286] D. M. Kim, I. H. Lee, and C. J. Song, “Uremic Encephalopathy: MR Imaging Findings and Clinical Correlation,” Ajnr American Journal of Neuroradiology 37, no. 9 (2016): 1604–1609.

[287] M. H. Rosner, F. Husain-Syed, T. Reis, C. Ronco, and R. Vanholder, “Uremic Encephalopathy,” Kidney International 101, no. 2 (2022): 227–241.

[288] H. Xie, N. Yang, C. Yu, and L. Lu, “Uremic Toxins Mediate Kidney Diseases: The Role of Aryl Hydrocarbon Receptor,” Cellular & Molecular Biology Letters 29, no. 1 (2024): 38.

[289] S. Liabeuf, M. Pepin, C. F. M. Franssen, et al., “Chronic Kidney Disease and Neurological Disorders: Are Uraemic Toxins the Missing Piece of the Puzzle?,” Nephrology, Dialysis, Transplantation 37, no. Suppl 2 (2021): ii33–ii44.

[290] D. Viggiano, C. A. Wagner, G. Martino, et al., “Mechanisms of Cognitive Dysfunction in CKD,” Nature Reviews Nephrology 16, no. 8 (2020): 452–469.

[291] B. Sun, M. Ramberger, K. C. O'Connor, R. J. M. Bashford-Rogers, and S. R. Irani, “The B Cell Immunobiology That Underlies CNS Autoantibody-mediated Diseases,” Nature reviews Neurology 16, no. 9 (2020): 481–492.

[292] W. Jing, B. Jabbari, and N. D. Vaziri, “Uremia Induces Upregulation of Cerebral Tissue Oxidative/Inflammatory Cascade, Down-regulation of Nrf2 Pathway and Disruption of Blood Brain Barrier,” American journal of translational research 10, no. 7 (2018): 2137–2147.

[293] L. Lu, N. Hu, H. Chen, et al., “Cisplatin-induced Acute Kidney Injury Increased Brain 5-hydroxytryptamine Levels Partly due to the Hippuric Acid-induced Upregulation of CYP2D4 Expression and Function in the Brain of Rats,” Drug Metabolism and Disposition 53, no. 5 (2025): 100068.

[294] L. Jiang, X. Y. Sun, S. Q. Wang, et al., “Indoxyl Sulphate-TNFα Axis Mediates Uremic Encephalopathy in Rodent Acute Kidney Injury,” Acta Pharmacologica Sinica 45, no. 7 (2024): 1406–1424.

[295] M. Karbowska, J. M. Hermanowicz, A. Tankiewicz-Kwedlo, et al., “Neurobehavioral Effects of Uremic Toxin-indoxyl Sulfate in the Rat Model,” Scientific Reports 10, no. 1 (2020): 9483.

[296] C. Y. Sun, J. R. Li, Y. Y. Wang, et al., “p-Cresol Sulfate Caused Behavior Disorders and Neurodegeneration in Mice with Unilateral Nephrectomy Involving Oxidative Stress and Neuroinflammation,” International Journal of Molecular Sciences 21, no. 18 (2020): 6687.

[297] S. Adesso, I. Paterniti, S. Cuzzocrea, et al., “AST-120 Reduces Neuroinflammation Induced by Indoxyl Sulfate in Glial Cells,” Journal of Clinical Medicine 7, no. 10 (2018): 365.

[298] S. Zimmermann, A. Mathew, O. Bondareva, et al., “Chronic Kidney Disease Leads to Microglial Potassium Efflux and Inflammasome Activation in the Brain,” Kidney International 106, no. 6 (2024): 1101–1116.

[299] E. J. Kim, Y. R. Ham, J. A. Shin, et al., “Omega-3 Polyunsaturated Fatty Acid Attenuates Uremia-Induced Brain Damage in Mice,” International Journal of Molecular Sciences 22, no. 21 (2021): 11802.

[300] J. A. Shin, H. Park, H. Choi, et al., “ω-3 Polyunsaturated Fatty Acids Improve the Blood-Brain-Barrier Integrity in Contrast-Induced Blood-Brain-Barrier Injury in Uremic Mice,” International Journal of Molecular Sciences 24, no. 15 (2023): 12168.

[301] H. F. Hasan, L. A. Rashed, and N. M. El Bakary, “Concerted Outcome of Metformin and Low Dose of Radiation in Modulation of Cisplatin Induced Uremic Encephalopathy via Renal and Neural Preservation,” Life Sciences 276 (2021): 119429.

[302] D. Ragab, D. M. Abdallah, and H. S. El-Abhar, “The Dual Reno- and Neuro-protective Effects of Dimethyl Fumarate against Uremic Encephalopathy in a Renal Ischemia/Reperfusion Model,” Pharmacol Rep 72, no. 4 (2020): 969–983.

[303] L. Xu and R. Zhang, “Nobiletin Alleviates Brain Injury in Uremic Mice and Inhibits Indoxyl Sulfate-induced Neurotoxicity in HT22 Cells through the Phosphatidylinositol 3-kinase/Protein Kinase B Signaling Pathway,” Cytojournal 22 (2025): 27.

[304] F. Sharifi, P. Reisi, and M. Malek, “Angiotensin 1 Receptor Antagonist Attenuates Acute Kidney Injury-induced Cognitive Impairment and Synaptic Plasticity via Modulating Hippocampal Oxidative Stress,” Life Sciences 234 (2019): 116775.

[305] M. R. Dobbs, “Toxic Encephalopathy,” Seminars in Neurology 31, no. 2 (2011): 184–193.

[306] A. C. Martins, B. N. Krum, L. Queirós, et al., “Manganese in the Diet: Bioaccessibility, Adequate Intake, and Neurotoxicological Effects,” Journal of Agricultural and Food Chemistry 68, no. 46 (2020): 12893–12903.

[307] W. Yao, D. L. Gallagher, and A. M. Dietrich, “Risks to Children from Inhalation of Aerosolized Aqueous Manganese Emitted from Ultrasonic Humidifiers Can be Greater than for Corresponding Ingestion,” Water Research 207 (2021): 117760.

[308] Z. Zhang, J. Yang, Q. Zhou, et al., “The Role and Mechanism of the cGAS-STING Pathway-mediated ROS in Apoptosis and Ferroptosis Induced by Manganese Exposure,” Redox Biology 85 (2025): 103761.

[309] X. Zhang, J. Liu, S. Zhong, et al., “Exposure to Manganese Induces Autophagy-Lysosomal Pathway Dysfunction-Mediated Tauopathy by Activating the cGAS-STING Pathway in the Brain,” Environ Health (Wash) 3, no. 2 (2024): 199–212.

[310] H. Hong, S. Liu, T. Yang, et al., “Manganese Exposure Induces Parkinsonism-Like Symptoms by Serpina3n-TFEB-v/p-ATPase Signaling Mediated Lysosomal Dysfunction,” Cell Biology and Toxicology 41, no. 1 (2025): 34.

[311] Y. Jia, B. He, K. Chen, et al., “Excessive Mitochondrial Stress Response Triggers Neuronal Injury through the Persistent eIF2α Phosphorylation in Mice Exposed to Manganese,” Journal of Hazardous Materials 496 (2025): 139407.

[312] Z. Tao, X. Zhang, J. Chen, et al., “Manganese Stimulates Ferroptosis to Trigger Neurotoxicity in Mice and HT22 Cells: The Role of NCOA4-mediated Ferritinophagy,” Neurochemistry International 190 (2025): 106065.

[313] D. Budinger, S. Alhaque, R. González-Méndez, et al., “An iPSC-derived Neuronal Model Reveals manganese's Role in Neuronal Endocytosis, Calcium Flux and Mitochondrial Bioenergetics,” Iscience 28, no. 9 (2025): 113311.

[314] Z. Mei, G. Liu, B. Zhao, Z. He, and S. Gu, “Emerging Roles of Epigenetics in Lead-induced Neurotoxicity,” Environment International 181 (2023): 108253.

[315] D. Peng, P. Wei, Z. Li, R. Wei, H. Li, and S. Li, “The Role of P62/Nrf2/Keap1 Signaling Pathway in Lead-Induced Neurological Dysfunction,” CNS neuroscience & therapeutics 31, no. 9 (2025): e70566.

[316] X. Liu, C. Huang, M. Wang, L. Hu, Y. Song, and G. Jiang, “Single-Nucleus Transcriptomics Reveals Prenatal and Postnatal Pb Exposure-Induced Cell-Specific Neurotoxicity and Dysregulated Microglia-Neuron Communication in Mice Brain,” Environmental Science & Technology 59, no. 26 (2025): 13157–13168.

[317] Y. Son, Y. J. Jeong, H. Y. Kim, et al., “Behavioral and Neurochemical Changes in Mice Induced by Low-level Lead Exposure: Implications for ADHD and Conduct Disorders,” Ecotoxicol Environ Saf 302 (2025): 118735.

[318] Y. Wang, X. Shen, R. Guan, et al., “Lead Induces Mitochondrial Dysregulation in SH-SY5Y Neuroblastoma Cells via a lncRNA/circRNA-miRNA-mRNA Interdependent Networks,” International Journal of Molecular Sciences 26, no. 14 (2025): 6851.

[319] A. Jedličková, D. Kristeková, Z. Husáková, et al., “Inhaled Lead Nanoparticles Enter the Brain through the Olfactory Pathway and Induce Neurodegenerative Changes Resembling Tauopathies,” ACS Nano 19, no. 13 (2025): 12799–12826.

[320] R. Hao, F. Li, D. Sun-Waterhouse, and D. Li, “The Roles of MicroRNAs in Cadmium Toxicity and in the Protection Offered by Plant Food-derived Dietary Phenolic Bioactive Substances against Cadmium-induced Toxicity,” Food Chemistry 460 (2024): 140483.

[321] K. Gustin, F. Tofail, M. Vahter, and M. Kippler, “Cadmium Exposure and Cognitive Abilities and Behavior at 10 Years of Age: A Prospective Cohort Study,” Environment International 113 (2018): 259–268.

[322] H. Wang, J. J. Lim, H. Gu, Z. Xia, and J. Y. Cui, “Cadmium-induced Gut Dysbiosis Precedes the Onset of Hippocampus-dependent Learning and Memory Deficits in Mice,” Toxicology 518 (2025): 154265.

[323] Y. Wang, D. Peng, X. Zhang, et al., “PLCβ4 driven by Cadmium-exposure during Gestation and Lactation Contributes to Cognitive Deficits by Suppressing PIP2/PLCγ1/CREB/BDNF Signaling Pathway in Male Offspring,” Journal of Hazardous Materials 474 (2024): 134756.

[324] Y. Xu, H. Hong, X. Lin, et al., “Chronic Cadmium Exposure Induces Parkinson-Like Syndrome by Eliciting Sphingolipid Disturbance and Neuroinflammation in the Midbrain of C57BL/6J Mice,” Environmental Pollution 337 (2023): 122606.

[325] P. Deng, H. Zhang, L. Wang, et al., “Long-term Cadmium Exposure Impairs Cognitive Function by Activating Lnc-Gm10532/m6A/FIS1 Axis-mediated Mitochondrial Fission and Dysfunction,” Science of the Total Environment 858 (2023): 159950.

[326] G. Li, C. Sun, L. Zhu, Y. Zeng, J. Li, and Y. Mei, “High Cadmium Exposure Impairs Adult Hippocampal Neurogenesis via Disruption of Store-operated Calcium Entry,” Ecotoxicol Environ Saf 286 (2024): 117162.

[327] H. J. Sun, P. Xiang, J. Luo, et al., “Mechanisms of Arsenic Disruption on Gonadal, Adrenal and Thyroid Endocrine Systems in Humans: A Review,” Environment International 95 (2016): 61–68.

[328] K. Liu, T. Tao, R. Li, H. Wang, L. Wang, and H. Wu, “Early-Life Arsenic Exposure Induces Histone H3K9 Methylation Causing PANoptosis and Neurodevelopmental Impairments in Offspring,” Biological Trace Element Research 204, no. 3 (2025): 1603–1621.

[329] C. Tian, Q. Wu, F. Chen, et al., “Dynamic Telomere Length Response to Neurodevelopmental Arsenic Exposure: Insights into Transcriptional Regulation and Neuronal Morphogenesis,” Environ Health (Wash) 3, no. 9 (2025): 1031–1042.

[330] L. Zhang, Y. Xiao, D. Wang, et al., “NOX2/NLRP3-Inflammasome-Dependent Microglia Activation Promotes as(III)-Induced Learning and Memory Impairments in Developmental Rats,” Toxics 13, no. 7 (2025): 538.

[331] A. Dutta, R. Roy, M. Pandey, et al., “Arsenic-induced Mice Model of Parkinson's Disease: Revealing the Neurotoxicity of Arsenic through Mitochondrial Complexes Inhibition and Dopaminergic Neurodegeneration in the Substantia nigra Region of Brain,” Brain Research 1851 (2025): 149493.

[332] A. Dutta, B. C. Phukan, R. Roy, P. Bhattacharya, D. Kumar, and A. Borah, “Arsenic Exposure Induces Cognitive Impairment in Mice with Increased Acetylcholinesterase Activity and Inflammation in the Cortex and Hippocampus: Implications for Alzheimer's Disease,” Curr Alzheimer Res 22, no. 10 (2025): 745–756.

[333] S. Sarkar, A. Pandey, B. Khan, and A. B. Pant, “Integrative Assessment of RNA Sequencing and in Silico Analysis to Pinpoint mRNAs, lncRNAs, and circRNAs Interactions with miRNAs Underlying Arsenic-induced Neurotoxicity,” BMC Genomics [Electronic Resource] 26, no. 1 (2025): 813.

[334] W. Hao, X. Zhu, Z. Liu, et al., “Aluminum Exposure Induces central Nervous System Impairment via Activating NLRP3-medicated Pyroptosis Pathway,” Ecotoxicol Environ Saf 264 (2023): 115401.

[335] C. He, Q. Hu, C. Liu, et al., “Aluminum Induces Neurotoxicity through the MicroRNA-98-5p/Insulin-Like Growth Factor 2 Axis,” Acs Chemical Neuroscience 16, no. 3 (2025): 329–341.

[336] L. Yang, G. Qi, W. Rao, et al., “Aluminum Causes Irreversible Damage to the Development of Hippocampal Neurons by Regulating m6A RNA Methylation,” Toxicology Letters 399 (2024): 34–42.

[337] Y. Zhang, L. Jia, Z. Wang, et al., “Alumina Nanoparticles Induce Learning and Memory Impairment in a Particle Size-dependent and Time-dependent Manner,” Ecotoxicol Environ Saf 295 (2025): 118177.

[338] J. Gao, W. Liu, J. Liu, N. Hao, J. Pei, and L. Zhang, “The Role of Acetylation and Methylation of Rat Hippocampal Histone H3 in the Mechanism of Aluminum-Induced Neurotoxicity,” Neurochemical Research 49, no. 2 (2024): 441–452.

[339] M. Prüst, J. Meijer, and R. H. S. Westerink, “The Plastic Brain: Neurotoxicity of Micro- and Nanoplastics,” Particle and Fibre Toxicology 17, no. 1 (2020): 24.

[340] Y. Chen, Y. Nan, L. Xu, et al., “Polystyrene Nanoplastics Exposure Induces Cognitive Impairment in Mice via Induction of Oxidative Stress and ERK/MAPK-mediated Neuronal Cuproptosis,” Particle and Fibre Toxicology 22, no. 1 (2025): 13.

[341] X. Lu, Q. Luo, J. Zhao, M. Li, and D. Liu, “Revealing the Underlying Mechanisms of Nanoplastics Induces Neuroinflammation: From Transcriptomic Analysis to in Vivo and in Vitro Validation,” Ecotoxicol Environ Saf 298 (2025): 118311.

[342] X. Li, E. He, G. Chen, et al., “Intergenerational Neurotoxicity of Polystyrene Nanoplastics in Offspring Mice Is Mediated by Dysfunctional Microbe-gut-brain Axis,” Environment International 192 (2024): 109026.

[343] G. Yang, M. Li, X. Zheng, et al., “Trehalose Acts as a Mediator: Imbalance in Brain Proteostasis Induced by Polystyrene Nanoplastics via Gut Microbiota Dysbiosis during Early Life,” ACS Nano 19, no. 20 (2025): 19233–19254.

[344] X. Cai, Q. Yang, J. Chen, et al., “Early-life Microplastic Exposure Elicits ADHD-Like Behaviors by Disrupting Dopaminergic Neurodevelopment in Zebrafish,” Journal of Hazardous Materials 496 (2025): 139466.

[345] A. Dai, X. Liu, Y. Chen, et al., “Co-exposure to Ozone and Polystyrene Nanoplastic Exacerbates Cognitive Impairment and Anxiety-Like Behavior by Regulating Neuronal Pyroptosis in Mice,” Environment International 199 (2025): 109501.

[346] P. Zhang, G. Lu, L. Zhang, Z. Yan, J. Zhang, and K. Ding, “Unraveling the Mechanism of Brain Damage in Carassius auratus by Polypropylene Microplastics and Oxytetracycline via the Brain-gut-microbiota Axis,” Journal of Environmental Management 392 (2025): 126711.

[347] P. Javanbakht, A. Talebinasab, R. Asadi-Golshan, M. Shabani, I. R. Kashani, and S. Mojaverrostami, “Effects of Quercetin against Fluoride-induced Neurotoxicity in the Medial Prefrontal Cortex of Rats: A Stereological, Histochemical and Behavioral Study,” Food and Chemical Toxicology 196 (2025): 115126.

[348] S. Ghotbinasab, A. A. Oroojan, M. A. Behmanesh, N. Amirgholamy, A. H. Nasiri, and S. Alboghobeish, “Severe Neurotoxicity Induced by the Combined Exposure to Cadmium and High-fat Diet: Protective Role of Naringin against Oxidative, Mitochondrial, and Inflammatory Brain Damage,” Neurotoxicology 111 (2025): 103306.

[349] C. E. Onukak, O. M. Femi-Akinlosotu, A. A. Obasa, et al., “Epigallocatechin -3- gallate Mitigates Diazinon Neurotoxicity via Suppression of Pro-inflammatory Genes and Upregulation of Antioxidant Pathways,” BMC Neuroscience [Electronic Resource] 26, no. 1 (2025): 22.

[350] S. Wen, Y. Zhao, L. Wang, and Y. Yuan, “Daidzein Attenuates Cadmium-Induced Neurotoxicity via Inhibiting Apoptosis and Mitophagy in the Cerebral Cortex of Sprague-Dawley Rats,” Journal of Biochemical and Molecular Toxicology 39, no. 5 (2025): e70299.

[351] H. Y. Ma, J. Wang, J. Wang, et al., “Luteolin Attenuates Cadmium Neurotoxicity by Suppressing Glial Inflammation and Supporting Neuronal Survival,” International Immunopharmacology 152 (2025): 114406.

[352] L. J. Chen, Y. Liu, J. L. Liu, et al., “Lycopene Ameliorates Di-(2-ethylhexyl) phthalate-induced Neurotoxicity in Mice via the Gut-brain Axis,” Phytomedicine 145 (2025): 157057.

[353] B. Shen, G. Yang, M. Lv, et al., “Cannabidiol Attenuates Methamphetamine-induced Oxidative Neurotoxicity via Regulating Transient Receptor Potential Vanilloid Type 1,” Phytomedicine 145 (2025): 157015.

[354] S. E. Owumi, B. J. Oluwawibe, J. Chimezie, et al., “An in Vivo and in Silico Probing of the Protective Potential of Betaine against Sodium Fluoride-induced Neurotoxicity,” BMC Pharmacol Toxicol 25, no. 1 (2024): 87.

[355] M. Bolat, T. E. Yilmaz, M. Çeğindir, et al., “Syringic Acid Alleviates Cadmium-induced Neurotoxicity in Rats by Modulating Cellular Signaling Pathways,” International Immunopharmacology 158 (2025): 114816.

[356] I. Bolat, S. Yildirim, Y. S. Saglam, et al., “β-Caryophyllene Attenuates Cadmium Induced Neurotoxicity in Rats by Modulating Different Cellular Signaling Pathways,” Neurotoxicology 108 (2025): 206–217.

[357] C. Prakash, J. Tyagi, K. V. Singh, G. Kumar, and D. Sharma, “Eugenol Attenuates Aluminium-induced Neurotoxicity in Rats by Inhibiting the Activation of STAT3 and NF-кB,” Metabolic Brain Disease 40, no. 1 (2025): 87.

[358] Y. Dag, S. Yildirim, E. Sengul, F. Aykurt, M. Gok, and A. Cinar, “Therapeutic Role of Melatonin on Acrylamide-induced Neurotoxicity via Reducing ER Stress, Inflammation, and Apoptosis in a Rat Model,” BMC Pharmacol Toxicol 26, no. 1 (2025): 57.

[359] J. Gao, J. Shen, L. Gao, et al., “Melatonin Improves Synaptic Morphological Plasticity of Adolescent Male Rats after Perinatal BDE-209 Exposure via SIRT1-mediated LIMK1 and CREB Signaling,” Neurotoxicology 111 (2025): 103331.

[360] S. Sanajou, A. Yirün, G. Demirel, P. Erkekoğlu, G. Şahin, and T. Baydar, “The Ameliorative Potential of Metformin against Aluminum-induced Neurotoxicity: Insights from in Vitro Studies,” Journal of Applied Toxicology 45, no. 2 (2025): 245–255.

[361] D. Tao, Y. Xia, Q. Liao, X. Yang, L. Zhang, and C. Xie, “Rapamycin Mitigates Neurotoxicity of Fluoride and Aluminum by Activating Autophagy through the AMPK/mTOR/ULK1 Pathway in Hippocampal Neurons and NG108-15 Cells,” Scientific Reports 15, no. 1 (2025): 9801.

[362] N. Rasheed, H. K. Hussain, Z. Rehman, et al., “Co-administration of Coenzyme Q10 and Curcumin Mitigates Cognitive Deficits and Exerts Neuroprotective Effects in Aluminum Chloride-induced Alzheimer's Disease in Aged Mice,” Experimental Gerontology 199 (2025): 112659.

[363] C. Guo, Q. Huang, Y. Wang, et al., “Therapeutic Application of Natural Products: NAD⁺ Metabolism as Potential Target,” Phytomedicine 114 (2023): 154768.

[364] X. Zhang, Q. Li, X. Ye, et al., “The Impacts of Natural Product Miltirone and the CYP2D6 Pharmacogenetic Phenotype on Fluoxetine Metabolism,” Frontiers in pharmacology 15 (2024): 1373048.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.